{"filing":{"accession_number":"0001213900-26-078937","cik":"0001415397","ticker":"RAPH","company_name":"Raphael Pharmaceutical Inc.","form":"8-K","filing_date":"2026-07-17","report_date":null,"primary_document":"ea0298326-8k_raphael.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/ea0298326-8k_raphael.htm"},"events":[{"id":18608,"run_id":16730,"accession_number":"0001213900-26-078937","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses two significant executive departures: Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. While the section also mentions the appointment of Uri Tadelis as CFO, the principal disclosed actions center on the departures of two senior officers, including the CFO and Board Chairman. Both resignations are stated to be voluntary and without disagreement with the Company.","company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","filing_date":"2026-07-17","form":"8-K","submitted_at":null,"items":[{"id":17476,"accession_number":"0001213900-26-078937","item_number":"5.02","item_title":"Departure","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two significant executive departures: Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. While the section also mentions the appointment of Uri Tadelis as CFO, the principal disclosed actions center on the departures of two senior officers, including the CFO and Board Chairman. Both resignations are stated to be voluntary and without disagreement with the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T13:21:37.145437+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17476,"accession_number":"0001213900-26-078937","item_number":"5.02","item_title":"Departure","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses two significant executive departures: Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. While the section also mentions the appointment of Uri Tadelis as CFO, the principal disclosed actions center on the departures of two senior officers, including the CFO and Board Chairman. Both resignations are stated to be voluntary and without disagreement with the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T13:21:37.145437+00:00","company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","filing_date":"2026-07-17"}]}